ClinicalTrials.gg
RecruitingNCT07842367IMPACTUpdated Sep 30, 2026

Inflammation and Medical Provider Attitudes, Cognition, and Treatment Decisions Study

A Phase 2 interventional study of Influenza vaccine and Placebo in Decision-Making, Patient Care and Treatment Decisions, sponsored by University of Arkansas, Fayetteville. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Arkansas, Fayetteville · Phase 2, Interventional, and Health services research

How we know

Updated Sep 30, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind clinical trial involving emergency medicine and internal medicine healthcare providers as participants. The intervention involves the administration of the seasonal influenza vaccine or a saline placebo; this protocol is used in psychoneuro-immunology to simulate a state of mild illness. The primary aim is to examine whether acute inflammation induced by receiving the vaccine affects decision-making on standardized psychological reaction time tasks and questionnaires. Participants attend two laboratory sessions on consecutive days, receive either a seasonal influenza vaccine or a saline placebo at the first session, provide blood samples to measure inflammatory cytokines, and complete a series of standardized assessments of medical decision-making and social attitudes. Participants who received the placebo during the first session will receive the vaccine during the second session.

Overall, the study is designed to examine how adverse provider conditions particularly acute inflammation, burnout, and concerns about one's own health affect provider judgments and healthcare-related decision-making. The primary hypothesis is that providers experiencing greater adverse conditions at the time of research participation would have altered decision-making compared to those experiencing fewer adverse conditions.

Read the detailed description

Participants will provide informed consent during a call (Zoom, Teams, Phone) with the University of Arkansas research team. The research team member will explain the study procedures to the participants and will give them the opportunity to ask questions. During the call, they will review the electronic consent form and will sign the form after all of their questions have been answered. They will receive a paper copy of the consent documents to review one more time when they arrive at the first research session at their site.

Participants will complete two lab sessions on consecutive days (scheduled as close to 24-hours apart as possible) at a collaborating research site. At each site, a member of the local team will coordinate the sessions, including providing instructions before participants complete various study tasks. During each session, participants will complete standardized measures of decision-making that will allow us to comprehensively document how adverse provider conditions (acute inflammation, burnout, stress, concern about own health) affect objectivity in decision-making across multiple domains. These standardized measures include reaction time tasks and questionnaires. Participants will also complete questionnaires that assess demographic information, personality information, and questions about their experiences with adverse provider conditions (burnout, stress, other workplace demands, mood, concerns about own health). During each session, participants will provide blood samples (\~3mL) that will be assayed for pro-inflammatory cytokines interleukin-6 and interleukin-1beta. Participants will be randomly assigned to either the experimental or control condition using stratified permuted block randomization. Those in the experimental condition will receive the influenza vaccine at the end of Session 1 and those in the control condition will receive a saline placebo injection instead. We will use a double-blind design so that neither the participant nor the research assistant administering the decision-making tasks will know the condition.

At the end of the second session, participants will be debriefed and informed about the condition they were assigned to (up until this point, the research coordinator and participant will be blind to participant condition). Those in the control condition will receive the vaccine before they leave.

02

Conditions studied

  • Decision-Making
  • Patient Care
  • Treatment Decisions

Keywords

  • Decision making
  • Patient Care
03

In context

Lead sponsor

University of Arkansas, Fayetteville is the lead sponsor of 29 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthcare providers currently employed in emergency medicine or internal medicine
  • Must be one of the following: Resident, fellow, attending, or advanced practice provider (NP, PA)
  • Individual is able to travel to the research site for sessions
  • Has not had an acute viral or bacterial infection within the previous 14 days
  • Has not taken an antiviral medication such as Tamiflu in the previous 48 hours
  • Has not taken or in the previous 30 days

Exclusion criteria

Exclusion Criteria:

  • Does not want to receive a flu vaccine as part of the study
  • Has received a flu vaccine this season already (after August of current year)
  • Has had a prior allergic reaction or bad side effect, including Guillain-Barre, due to a flu vaccine or another vaccine
  • Is allergic to eggs or have had an adverse reaction to egg-derived vaccine
  • Is pregnant or suspects a possible pregnancy
  • Has congenital or acquired immunodeficiency such as common variable immunodeficiency (CVID) or /AIDS
  • Has an active hematologic (like leukemia, lymphoma, myeloma)
  • Has Type 1 diabetes
  • Has Graft vs. Host Disease
  • Uses aspirin, ibuprofen (i.e., NSAIDs), acetaminophen, or naproxen daily
  • Uses or daily
  • Is currently receiving systemic chemotherapy and/or immunotherapy
  • Has had changes in daily prescription medication in the last 3 months (starting, stopping, changing dose)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Influenza Vaccine Injection

    Receives the influenza vaccine at the end of Session 1

    Biological: Influenza vaccine

  • Placebo comparator
    Placebo Injection

    Receives a saline placebo injection at the end of Session 1

    Other: Placebo

Interventions

  • BiologicalInfluenza vaccine

    A single administration of a seasonal trivalent cell-based influenza vaccine delivered by injection into the arm at the end of the first study session.

  • OtherPlacebo

    Control group will receive a saline placebo injection at the end of Session 1

06

What researchers measure

Primary outcomes

  1. Testing Automatic Judgments: "Implicit Association Test"

    This task calculates a "d" score across trials to quantify the strength of implicit associations. Higher d scores indicate more negative automatic attitudes.

    Time frame: 2 days

  2. Testing Deliberate Judgments: "Feeling Thermometers"

    Explicit attitudes are assessed via 100-point Feeling Thermometers that ask for feeling toward different patient groups. Lower values indicate more negative attitudes.

    Time frame: 2 days

Secondary outcomes

  1. Questionnaire Assessing Social Avoidance: "Patient Sorting Task"

    A behavioral decision-making task order patients within an array of three. The three patients are arranged in an order in which the participant would choose to see them. The outcome is the number of trials when a patient from a target group is seen later than a patient from a control group. Higher values indicate greater potential for treatment inconsistencies.

    Time frame: 1 day

  2. Questionnaire Assessing Perception of Others' Pain: "Threshold for Detecting Pain on Faces"

    Participants will see 11 images of targets of different racial groups that have each been morphed to go from no pain to high pain, responding to a yes/no question about whether the target is in pain in each image. The threshold at which participants begin perceiving pain will be calculated for each target and averaged within racial groups. Differences between groups indicate potential for greater treatment inconsistencies.

    Time frame: 2 days

  3. Questionnaire Assessing Cognitive Depletion: "Stroop Task"

    To measure the delay in reaction time between neutral and incongruent stimuli. The task calculates an interference score across many trials to show the difference in response latency between incongruent and congruent trials. Greater interference is a measure of cognitive depletion.

    Time frame: 2 days

  4. Questionnaire Assessing Motivation: "Motivation to Respond without Prejudice Scale"

    It is administered on a scale of 1 to 9, and the questions are about both internal and external motivation. Higher scores represent more motivation.

    Time frame: 2 days

07

Study locations

3 of 3 sites recruiting
  • University of Arkansas for Medical Sciences
    Fayetteville, Arkansas 72703, United States
    Recruiting
    • Roy Kamoga, MD · Contactgkamoga@uams.edu · 785-639-3110
    • Roy Kamoga, MD · Principal investigator
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87106, United States
    Recruiting
  • Carilion Medical Center
    Roanoke, Virginia 24016, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 25, 2026
StartEst.
Sep 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • University of Arkansas for Medical Sciences · Fayetteville, United Statesno status→Recruiting
  • University of New Mexico Health Sciences Center · Albuquerque, United Statesno status→Recruiting
  • Carilion Medical Center · Roanoke, United Statesno status→Recruiting
Sep 30, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 2 updates
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • University of Arkansas for Medical Sciences · Fayetteville, United Statesno status→Recruiting
    • University of New Mexico Health Sciences Center · Albuquerque, United Statesno status→Recruiting
    • Carilion Medical Center · Roanoke, United Statesno status→Recruiting
  2. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07842367
Lead sponsor
University of Arkansas, Fayetteville
Responsible party
Sponsor
First posted
Sep 25, 2026
Start date
Sep 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Anastasia Makhanova, PhD
Contact
ammakhan@uark.edu
479-575-8798

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion